An earlier study has already confirmed that IL-19 interacts with IL-20RA and that IL20RA-triggered JAK1-STAT3 promotes the stemness of BC cells and that inhibiting IL20RA+ cells may be a potential strategy to minimize the stemness and reduce the drug-resistance of BC cells (Gao et al., 2021). Here, JAK1 is linked to breast cancer.